On January 13, 2021, the Lifeflow iliac artery bifurcation stent system developed by SZXJ Medical Technology Group was registered and approved by the National Medical Products Administration (NMPA) of China. This innovative product is used for the endovascular treatment of abdominal iliac aneurysm or common iliac aneurysm. It is the first medical device developed in China to reconstruct the internal iliac artery intracavitary, bringing a new safe and effective treatment option for the majority of patients.
SZXJ iliac artery bifurcation stent system is composed of iliac artery bifurcation stent, iliac internal stent graft and its corresponding delivery system, which are used together. Different specifications of the iliac artery bifurcation stent and the iliac endograft stent have the same interface size to ensure a stable connection. At the same time, the iliac artery bifurcation stent can be directly connected to the branches of the abdominal aorta bifurcation stent, which can reduce the number of stents used in the operation, make the connection points between the stents less and relatively more stable, and not only can effectively reduce the stent connection The risk of endoleaks, and the reduction in the number of stents used reduces the treatment costs for patients. In addition, the delivery device of the iliac artery bifurcation stent adopts a post-release design, the operation is relatively simple, and the stent release is accurate. The SZXJ iliac artery bifurcation stent system also has a more comprehensive specification and size, can be applied to more clinical anatomical structures, and has a wider range of clinical applications.
SZXJ launched the iliac artery bifurcation stent system project research in 2012, and the product was approved to enter the "National Innovative Medical Device Special Review Program" in August 2017. The prospective, multi-center, single-group clinical research results of this product are outstanding. Clinical data show that its surgical success rate is 100%, and the patency rate of the internal iliac artery 180 days after surgery is 96.61%. The clinical application is safe and effective, and it has achieved high levels in the industry. Recognized.
Successfully implanted the SZXJ iliac artery stent system to treat patients with common iliac aneurysms. The 180-day CTA follow-up results after the operation showed that the stent morphology and structure were good, the bilateral iliac was unobstructed, and there were no adverse phenomena such as endoleak and stent displacement.
As a leading company in the field of minimally invasive interventions for cardiovascular and peripheral blood vessels, SZXJ has been committed to solving medical problems in the field from the beginning of its establishment, and has continued to introduce innovative interventional medical devices with independent intellectual property rights to meet my country's urgently needed clinical treatment needs . The approval of the iliac artery bifurcation stent system has enriched the SZXJ peripheral vascular intervention product portfolio, enabling SZXJ to further improve its platform layout in the field of aortic endovascular treatment. In the future, SZXJ will continue to insist on independent innovation, and work with industry experts to promote the development and marketing of more clinically urgently needed innovative medical device products to benefit the majority of patients.